Newswise — An improved fluorescence method for direct optimization of challenging biopharmaceuticals formulations is showcased in an original research article in the December 2018 issue of SLAS Technology. This study demonstrates the feasibility of using a steady-state/lifetime fluorescence plate reader for direct optimization of challenging formulation conditions and highlights the importance of performing formulation optimization under commercially relevant conditions.

The goal of protein formulation development is to identify optimal conditions for long-term storage of biopharmaceuticals. Certain commercial conditions, such as high protein concentration or turbid adjuvanted samples can impart additional challenges to biophysical characterization. Formulation screening studies for such conditions are usually performed using a simplified format in which the target protein is studied at a low concentration in a clear solution. The failure of study conditions to model the actual formulation environment may cause a loss of ability to identify the optimal condition for target proteins in their final commercial formulations.

In this study, authors from the University of Kansas (Lawrence, KS, USA) utilize a steady-state/lifetime fluorescence-based, high-throughput platform to develop a general workflow for direct formulation optimization under analytically challenging but commercially relevant conditions. A high-concentration monoclonal antibody (mAb) and an Alhydrogel-adjuvanted antigen are investigated. A large discrepancy in screening results is observed for both proteins under these two different conditions (simplified and commercially relevant).


Improved Fluorescence Methods for High-Throughput Protein Formulation Screening can be accessed for free for a limited time at For more information about SLAS and its journals, visit

A PDF of this article is available to credentialed media outlets upon request. Contact [email protected].

About our Society and Journals

SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 18,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).

SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).

Follow SLAS on Twitter at @SLAS_Org.

Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.

Follow SLAS on YouTube at SLASvideo. 

Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas). 

Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).